Naylor ML, Yun J, Arnold D. No evidence of disease activity achievement over 4 years of peginterferon beta-1a treatment in newly diagnosed patients with relapsing Multiple Sclerosis: subgroup analyses of ADVANCE/ATTAIN. EAN 2018, poster EPR2116.
Langetermijnresultaten PEARL-studie bevestigen effectiviteit en veiligheid van fremanezumab bij migraine
jul 2025 | Hoofdpijn